Apnimed, Inc. Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock
Apnimed, Inc. (APMD) reported Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock of 21.14 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-09-08.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToConversionOfPreferredStock · last filed 2026-09-08
- Apnimed, Inc. incremental common shares attributable to dilutive effect of conversion of preferred stock for the quarter ending 2026-06-30 was 21.14M shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock 3 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock 6 month |
|---|---|---|
| 2026-06-30 | 21.14M shares 10-Q · filed 2026-09-08 | 21.14M shares 10-Q · filed 2026-09-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B |